Amgen (AMGN): No Conclusion on Sensipar's Role in Death, Still Working with FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St rises on cooler inflation data, big bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
NPS Pharmaceuticals (NPSP) On Watch on Amgen (AMGN) Sensipar News
February 26, 2013 12:12 PM ESTNPS Pharmaceuticals, Inc. (Nasdaq: NPSP) is on watch on news the FDA has stopped all pediatric clinical trials of Amgen's (Nasdaq: AMGN) Sensipar after the recent death of a 14-year-old patient in a trial.... More
Trials of Amgen's (AMGN) Sensipar Halted Following Death - FDA
February 26, 2013 12:01 PM ESTThe U.S. Food and Drug Administration (FDA) has stopped all pediatric clinical trials of Amgen's (Nasdaq: AMGN) Sensipar (cinacalcet hydrochloride) after the recent death of a 14-year-old patient in a trial. FDA continues to gather information on the circumstances surrounding the patients death. Sensipar is a medication used to decrease the release of parathyroid hormone (PTH) from the parathyroid gland. Sensipar lowers high PTH levels leading to lower calcium levels in the blood; when calcium levels are too low it can result in health problems. FDA has approved Sensipar for use... More
